logo
Is the US forfeiting its Red Planet leadership to China's Mars Sample Return plan?

Is the US forfeiting its Red Planet leadership to China's Mars Sample Return plan?

Yahoo20 hours ago

When you buy through links on our articles, Future and its syndication partners may earn a commission.
While NASA's Mars Sample Return initiative is in political hot water, China is moving ahead on plotting out its rendezvous with the Red Planet.
New details of China's aims are emerging. China's intent is to haul back to Earth a Mars treasure trove or rock and soil via its Tianwen-3 mission. The plan calls for launch of two boosters in 2028 in support of their Mars Sample Return (MSR), which could send at least a pound (500 grams) of the extraterrestrial goodies back to Earth around 2031. A drill mounted on China's MSR lander would penetrate to a depth of 6.5 feet (2 meters) to collect several grams of subsurface samples, while a robotic arm will gather more than 400 grams of the foreign surface material from the landing site. Apparently, also on the agenda is use of a robotic helicopter. This drone, outfitted with an arm, is to be deployed for rock sampling at locations greater than 300 feet (over 100 meters) from the lander.
Just how impactful their potential success could be is now under discussion within the U.S. Given the value of Mars samples, not just for science but also to bolster plans for future crewed missions to Mars, robotic return of bits and pieces of the planet is seen by many as mandatory.
China's final pick of a landing zone will rely on a review of 86 preliminary landing sites. The chosen site will favor the emergence and preservation of evidence of traces of life and detection of potential biosignatures in the returned samples, according to a recent paper published in the journal Nature Astronomy.
"The mission aims to provide insights into nine scientific themes centered around the main focus of the search for extant and past life on Mars," explains lead author, Zengqian Hou of the Institute of Deep Space Sciences, Deep Space Exploration Laboratory, in Hefei, China.
Zengqian and colleagues have outlined where to collect, what to collect, how to collect, and how to analyze those precious Mars selections. "Collecting samples from Mars could provide accurate data on the signs of life," the research team explains.
Yiliang Li, a co-author of the Nature Astronomy paper, is an astrobiologist in the Earth sciences division at the University of Hong Kong (HKU). His role mainly involves leading an HKU group that is working on the selection of the landing site for the Tianwen-3 MSR mission.
According to an HKU statement, prime exploratory regions on Mars are those where liquid water was likely present in the planet's early history, areas rich in essential metallic nutrients, and sites where traces of Martian microbial activity could potentially be preserved for billions of years.
In the meantime, the search for promising sampling sites on Mars "remains an ongoing and active endeavor," the HKU statement adds.
Here in the United States, the White House released President Trump's 2026 Discretionary Funding Request that calls for ending financially unsustainable programs - including Mars Sample Return.
"In line with the Administration's objectives of returning to the Moon before China and putting a man on Mars, the Budget would reduce lower priority research and terminate unaffordable missions such as the Mars Sample Return mission that is grossly overbudget and whose goals would be achieved by human missions to Mars," the document says.
Indeed, over multiple years and multiple reviews of the joint NASA/European Space Agency MSR project there is a sticker-shock price tag; a last estimate was about $11 billion, with samples being returned to Earth in 2040.
MSR's mission cost was deemed too costly and would not be achieved on an acceptable time period by NASA's last, non-acting Administrator, Bill Nelson.
While techno-squabbles over MSR have been on-going, NASA's Perseverance Mars rover has been doggedly on the hunt within Jezero Crater. Since its touchdown in February 2021, the car-sized robot has been obediently gathering rock samples across the martian landscape. Some of those sealed specimens may well contain signs of past life on the Red Planet, and are deemed rocket-ready for pick-up and delivery to Earth.
The White House shutdown of the NASA/ESA MSR venture via the Trump budget "forfeits Mars Sample Return to China," declares a recent episode of the popular Mars Guy program, created by Steve Ruff, a leading planetary geologist at Arizona State University (ASU) in Tempe.
The President's budget forfeits the highest priority planetary science goal of MSR to China, but only if the US Congress agrees, Ruff notes.
In the interim, U.S. Senator Ted Cruz (R-Texas), Chairman of the Senate Committee on Commerce, Science, and Transportation, unveiled in early June his legislative directives for Senate Republicans' budget reconciliation bill, shaped to beat China to Mars and the Moon.
It dedicates almost $10 billion to win the new space race with China and ensure America dominates space by making, for one, targeted, critical investments in Mars-forward technology.
In the lawmaker's directive, Cruz calls for a Mars Telecommunications Orbiter, pegging $700 million for the commercial procurement of the dual-use orbiter. Its assignment is to handle both a Mars Sample Return mission to return core samples of Mars to Earth, as well as future human Mars missions.
But if China is on the MSR march to the Red Planet and NASA isn't, what about China returning already prime pre-selected specimens picked up by NASA's Perseverance Rover still busily at work within Jezero Crater?
"China's mission probably won't have access to comparably compelling samples as those collected by Perseverance because of engineering constraints that limit where it can land and the limited mobility options it will have," Ruff explains.
"I know from regular comments on my YouTube channel for Mars Guy that there's a commonly held view that the Chinese can or will pick up the samples in Jezero crater. But this simply can't happen given the engineering constraints of their Mars sample return mission as publicly presented. That mission will have neither the landing precision nor mobility on the surface to get to either the sample depot or to Perseverance," Ruff told Space.com. "So China is not going to save the NASA/ESA MSR mission."
On the other hand, China's Zengqian and colleagues state that exploration of Mars is a collective endeavor for all of humanity, writing in Nature Astronomy:
"The Tianwen-3 mission is committed to win–win cooperation, harmonious coexistence and shared prosperity through international cooperation. It actively seeks international partnerships through various channels and at various levels for joint scientific research, landing site selection and scientific payload development and testing."
Cooperation on MSR between the US and China, however, seems a bit of a dice roll, said Barry E. DiGregorio, founder and director of the International Committee Against Mars Sample Return based in Burlington, Ontario, Canada.
While China is inviting international cooperation, recent debates on tariffs between the two nations would seem to make the proposition difficult to hammer out.
"Now is the time to consider other options such as sending in-situ life detection instruments to Mars to settle the issue of extant life," DiGregorio told Space.com.
"We need to be sure what the next phase of Mars missions will be. With the continued push to get humans to Mars, astronaut safety should now take priority and that means making sure of biosafety concerns with any indigenous life forms that might be found," said DiGregorio.
While China is poised to become the first country to return potentially biologically active planetary material — including potential life forms — from beyond Earth, "the potential risk such substances might pose to terrestrial life, including humans, is a major concern," points out Yiliang at the University of Hong Kong.
To arrest that anxiety China plans to construct a specialized MSR facility on the outskirts of Hefei, the capital of Anhui, China. Within that facility, freshly-returned samples from Mars would undergo comprehensive biochemical and pathological testing under strict isolation from the Earth's environment.
"Only after it is conclusively determined that the samples contain no active biological agents or substances that could threaten the Earth's biosphere will they be released to designated laboratories for in-depth scientific analysis," concludes the University of Hong Kong statement.
The prospect of plucked collectibles to Earth for close-up inspection in state-of-the-art facilities is now literally "up for grabs" — but by what nation?
As voiced in a June 23 draft of candidate findings, statements of support/concern by the Mars Exploration Program Analysis Group (MEPAG), a community-based, interdisciplinary forum:
"Ambitious, first-of-their-kind missions like MSR come with challenges but NASA's history of success in difficult endeavors is what makes the US the international leader in deep space exploration," the document states. "Returning the scientifically selected samples that await us on Mars, as part of a balanced portfolio, will help to ensure the US does not cede leadership in deep space to other nations, such as China."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

Yahoo

time17 minutes ago

  • Yahoo

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone SHANGHAI & CAMBRIDGE, Mass., June 30, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis. Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer with FGFR2b overexpression and who are non-HER2 positive. FGFR2b overexpression was defined as 2+/3+ staining in ≥10% of tumor cells by centrally performed immunohistochemistry (IHC) testing. Gastric cancer is the fifth leading cause of cancer-related death worldwide, with nearly one million new cases and over 650,000 deaths globally each year 1, highlighting a critical unmet medical need. In China, there are over 350,000 new cases each year. The disease is associated with a poor prognosis, particularly in advanced stages where the five-year survival rate is less than 10%. There are currently no approved therapies specifically targeting FGFR2b overexpression in gastric cancer in China. "Bemarituzumab is the first FGFR2b inhibitor to demonstrate a statistically and clinically significant overall survival benefit in a randomized Phase 3 trial for the first-line treatment of FGFR2b-positive gastric cancer," said Dr. Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. "The success of the global Phase 3 FORTITUDE-101 study highlights the potential of bemarituzumab to redefine the standard of care for a patient population that has faced poor outcomes with existing therapies. We are proud to have contributed meaningfully to this pivotal trial, including a substantial number of patients enrolled in China. Based on these results, and the regulatory Breakthrough Designation, we plan to move rapidly toward regulatory submission in China to bring this transformative therapy to patients as quickly as possible." The most common treatment-emergent adverse events (>25%) in patients treated with bemarituzumab plus chemotherapy were reduced visual acuity, punctate keratitis, anaemia, neutropenia, nausea, corneal epithelium defect and dry eye. While ocular events were consistent with the Phase 2 experience and observed in both arms, they occurred with greater frequency and severity in the Phase 3 bemarituzumab arm. Detailed results from the trial will be shared at a future medical meeting. Zai Lab holds the development and commercialization rights for bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan. Bemarituzumab has been granted Breakthrough Therapy designation by the China Center for Drug Evaluation of the National Medical Products Administration for the treatment of FGFR2b-positive gastric and gastroesophageal junction adenocarcinoma. A Phase 3 study of bemarituzumab plus chemotherapy and nivolumab is also ongoing in patients with first-line gastric cancer, with data readout anticipated in H2 2025. About FGFR2b The FGFR2b protein (also known as fibroblast growth factor receptor 2b) is an emerging biomarker which, when overexpressed, promotes aberrant signaling leading to tumor cell proliferation.2 The FGFR2b protein is overexpressed by G/GEJ tumor cells in approximately 38% of patients with advanced G/GEJ cancer. FGFR2b protein overexpression is defined as 2+/3+ staining intensity on tumor cell membrane, as detected by immunohistochemistry (IHC) testing. In approximately 16% of patients with advanced G/GEJ cancer, FGFR2b protein overexpression is observed on ≥10% of tumor cells by IHC.3 About FORTITUDE-101 FORTITUDE-101 is a randomized, multi-center, double-blind, placebo-controlled Phase 3 study of bemarituzumab plus mFOLFOX6 versus placebo plus mFOLFOX6 as first-line therapy in advanced G/GEJ cancer with FGFR2b overexpression. The FORTITUDE-101 trial spanned 300 sites across 37 countries, with 547 patients enrolled. The primary outcome measure of the trial is overall survival in patients with FGFR2b ≥10% 2+/3+ tumor cell staining. Key secondary outcome measures include progression-free survival and overall response rate. Candidates were excluded from the trial if they were known to be human epidermal growth factor receptor 2 (HER2) positive. FORTITUDE-101 included more comprehensive ocular-related monitoring than previous studies of bemarituzumab. About Gastric Cancer in China Gastric cancer is the fifth most common cancer worldwide, while China bears one of the highest gastric cancer burdens in the world with an estimated 358,700 new cases and 260,400 deaths annually.4 In China, approximately 80% of gastric cancer patients are diagnosed at an advanced or metastatic stage5. For those diagnosed with Stage IV gastric cancer, the overall 5-year survival rate is less than 10%6. Patients with advanced gastric and GEJ cancer that overexpress the FGFR2b protein may be associated with poor prognosis7-10. About Zai Lab Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health worldwide. For additional information about Zai Lab, please visit or follow us at Zai Lab Forward Looking Statements This press release contains forward-looking statements relating to our future expectations, plans, and prospects, including, without limitation, statements regarding the prospects and plans for developing and commercializing bemarituzumab, the potential benefits of bemarituzumab, and the potential treatment of gastric and gastroesophageal junction cancer. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would," and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Our SEC filings can be found on our website at and the SEC's website at REFERENCES Bray F, et al. CA Cancer J Clin. 2024;74(3);229-263 Wainberg ZA, et al. Lancet Oncol. 2022;23(11):1430-40 Rha SY, et al. JCO Precis Oncol. 2025; 9 (e2400710). DOI:10.1200/PO-24-00710 Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. Health Commission of The People's Republic Of China N. National guidelines for diagnosis and treatment of gastric cancer 2022 in China (English version). Chin J Cancer Res. 2022;34(3):207-237. Li HQ, Zhang H, Zhang HJ, Wang YX, Wang XB, Hou HF. Survival of gastric cancer in China from 2000 to 2022: A nationwide systematic review of hospital-based studies. J Glob Health 2022;12:11014. Catenacci D, et al. Presented at American Society of Clinical Oncology; June 4-8, 2021; Online Virtual Scientific Program. Abstract 4010. Ahn S, et al. Mod Pathol. 2016;29:1095-1103. Ishiwata T. Front Biosci (Landmark Ed). 2018;23:626-639. Wainberg ZA, et al. Lancet Oncol. 2022;23:1430-1440. View source version on Contacts For more information, please contact: Investor Relations: Christine Chiou / Lina Zhang+1 (917) 886-6929 / +86 136 8257 / Media: Shaun Maccoun / Xiaoyu Chen+1 (857) 270-8854 / +86 185 0015 / Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

How can the James Webb Space Telescope see so far?
How can the James Webb Space Telescope see so far?

Yahoo

time18 minutes ago

  • Yahoo

How can the James Webb Space Telescope see so far?

Curious Kids is a series for children of all ages. If you have a question you'd like an expert to answer, send it to CuriousKidsUS@ How does the camera on the James Webb Space Telescope work and see so far out? – Kieran G., age 12, Minnesota Imagine a camera so powerful it can see light from galaxies that formed more than 13 billion years ago. That's exactly what NASA's James Webb Space Telescope is built to do. Since it launched in December 2021, Webb has been orbiting more than a million miles from Earth, capturing breathtaking images of deep space. But how does it actually work? And how can it see so far? The secret lies in its powerful cameras – especially ones that don't see light the way our eyes do. I'm an astrophysicist who studies galaxies and supermassive black holes, and the Webb telescope is an incredible tool for observing some of the earliest galaxies and black holes in the universe. When Webb takes a picture of a distant galaxy, astronomers like me are actually seeing what that galaxy looked like billions of years ago. The light from that galaxy has been traveling across space for the billions of years it takes to reach the telescope's mirror. It's like having a time machine that takes snapshots of the early universe. By using a giant mirror to collect ancient light, Webb has been discovering new secrets about the universe. Unlike regular cameras or even the Hubble Space Telescope, which take images of visible light, Webb is designed to see a kind of light that's invisible to your eyes: infrared light. Infrared light has longer wavelengths than visible light, which is why our eyes can't detect it. But with the right instruments, Webb can capture infrared light to study some of the earliest and most distant objects in the universe. Although the human eye cannot see it, people can detect infrared light as a form of heat using specialized technology, such as infrared cameras or thermal sensors. For example, night-vision goggles use infrared light to detect warm objects in the dark. Webb uses the same idea to study stars, galaxies and planets. Why infrared? When visible light from faraway galaxies travels across the universe, it stretches out. This is because the universe is expanding. That stretching turns visible light into infrared light. So, the most distant galaxies in space don't shine in visible light anymore – they glow in faint infrared. That's the light Webb is built to detect. Before the light reaches the cameras, it first has to be collected by the Webb telescope's enormous golden mirror. This mirror is over 21 feet (6.5 meters) wide and made of 18 smaller mirror pieces that fit together like a honeycomb. It's coated in a thin layer of real gold – not just to look fancy, but because gold reflects infrared light extremely well. The mirror gathers light from deep space and reflects it into the telescope's instruments. The bigger the mirror, the more light it can collect – and the farther it can see. Webb's mirror is the largest ever launched into space. The most important 'eyes' of the telescope are two science instruments that act like cameras: NIRCam and MIRI. NIRCam stands for near-infrared camera. It's the primary camera on Webb and takes stunning images of galaxies and stars. It also has a coronagraph – a device that blocks out starlight so it can photograph very faint objects near bright sources, such as planets orbiting bright stars. NIRCam works by imaging near-infrared light, the type closest to what human eyes can almost see, and splitting it into different wavelengths. This helps scientists learn not just what something looks like but what it's made of. Different materials in space absorb and emit infrared light at specific wavelengths, creating a kind of unique chemical fingerprint. By studying these fingerprints, scientists can uncover the properties of distant stars and galaxies. MIRI, or the mid-infrared instrument, detects longer infrared wavelengths, which are especially useful for spotting cooler and dustier objects, such as stars that are still forming inside clouds of gas. MIRI can even help find clues about the types of molecules in the atmospheres of planets that might support life. Both cameras are far more sensitive than the standard cameras used on Earth. NIRCam and MIRI can detect the tiniest amounts of heat from billions of light-years away. If you had Webb's NIRCam as your eyes, you could see the heat from a bumblebee on the Moon. That's how sensitive it is. Because Webb is trying to detect faint heat from faraway objects, it needs to keep itself as cold as possible. That's why it carries a giant sun shield about the size of a tennis court. This five-layer sun shield blocks heat from the Sun, Earth and even the Moon, helping Webb stay incredibly cold: around -370 degrees F (-223 degrees C). MIRI needs to be even colder. It has its own special refrigerator, called a cryocooler, to keep it chilled to nearly -447 degrees F (-266 degrees C). If Webb were even a little warm, its own heat would drown out the distant signals it's trying to detect. Once light reaches the Webb telescope's cameras, it hits sensors called detectors. These detectors don't capture regular photos like a phone camera. Instead, they convert the incoming infrared light into digital data. That data is then sent back to Earth, where scientists process it into full-color images. The colors we see in Webb's pictures aren't what the camera 'sees' directly. Because infrared light is invisible, scientists assign colors to different wavelengths to help us understand what's in the image. These processed images help show the structure, age and composition of galaxies, stars and more. By using a giant mirror to collect invisible infrared light and sending it to super-cold cameras, Webb lets us see galaxies that formed just after the universe began. Hello, curious kids! Do you have a question you'd like an expert to answer? Ask an adult to send your question to CuriousKidsUS@ Please tell us your name, age and the city where you live. And since curiosity has no age limit – adults, let us know what you're wondering, too. We won't be able to answer every question, but we will do our best. This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Adi Foord, University of Maryland, Baltimore County Read more: Could a telescope ever see the beginning of time? An astronomer explains How the James Webb Space Telescope has revealed a surprisingly bright, complex and element-filled early universe – podcast James Webb Space Telescope: An astronomer explains the stunning, newly released first images Adi Foord does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Momentus Awarded NASA Contract for In-Space Power System Demonstration
Momentus Awarded NASA Contract for In-Space Power System Demonstration

Business Wire

time2 hours ago

  • Business Wire

Momentus Awarded NASA Contract for In-Space Power System Demonstration

SAN JOSE, Calif.--(BUSINESS WIRE)--Momentus Inc. (NASDAQ: MNTS) ("Momentus" or the "Company"), a U.S. commercial space firm specializing in satellite solutions, transportation, and in-space infrastructure, has been awarded a contract by the National Aeronautics and Space Administration (NASA). The agreement will support the demonstration of a Power Processing Unit (PPU) for Hall Thrusters based upon CisLunar Industries' Modular Configurable Electric Power Converter (MCEPC) technologies, designed to advance high Delta V Dynamic Maneuver and in-space assembly (ISAM) operations. By demonstrating cutting-edge power conversion technologies in orbit, Momentus and CisLunar Industries are taking a crucial step towards enabling scalable in-space infrastructure. Share The expansion of space infrastructure demands sustainable and scalable electric power solutions that enhance efficiency while minimizing weight and size. Efficient power generation exceeding 1 kW is essential for high Delta V Dynamic Maneuvering, sensing, and ISAM applications, necessitating advancements in conversion technologies. Under the new contract managed by NASA's Flight Opportunities program based at the agency's Armstrong Flight Research Center in Edwards, California, Momentus will host a payload from CisLunar Industries to conduct in-orbit testing of next-generation PPU technology and power management systems. This PPU payload will be among several payloads that Momentus will carry aboard its Vigoride 7 Orbital Service Vehicle scheduled for launch no earlier than February 2026 on a SpaceX Transporter mission to Low Earth Orbit. The mission will validate the technology's performance, with real-time data transmissions to Momentus mission operations, enabling updates to PPU operating conditions in support of NASA's ISAM objectives. By demonstrating cutting-edge power conversion technologies in orbit, Momentus and CisLunar Industries are taking a crucial step towards enabling scalable in-space infrastructure. This mission not only advances NASA's ISAM objectives but also underscores the importance of efficient power management for future dual-use orbital operations and next-generation space operations. About Momentus Momentus is a U.S. commercial space company offering satellites, satellite components, and in-space transportation and infrastructure services. The Company offers satellites to support government and commercial customers for missions like communications, missile tracking, and cutting-edge science missions. Momentus offers services such as hosted payloads, support for in-space assembly, on-orbit servicing and refueling, and transportation of satellites to specific orbits. Forward-Looking Statements This press release contains certain statements which may constitute 'forward-looking statements' for purposes of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding the expected filing of the Company's Form 10-K and Form 10-Q and its management team's expectations, hopes, beliefs, intentions or strategies regarding the future, projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, and are not guarantees of future performance. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Momentus' control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to risks and uncertainties included under the heading 'Risk Factors' in the Annual Report on Form 10-K filed by the Company on April 9, 2025, as such factors may be updated from time to time in our other filings with the Commission, accessible on the Commission's website at and the Investor Relations section of our website at Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store